Pfizer Agrees To $345M Settlement Of Consumer, Third-Party EpiPen Claims
KANSAS CITY, Kan. — Pfizer Inc. and two related defendants have agreed to a $345 million class settlement of claims by consumers and third-party payers that they overpriced the EpiPen epinephrine...To view the full article, register now.
Already a subscriber? Click here to view full article